Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
16 March 1992Website:
http://www.aptose.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:53:47 GMTDividend
Analysts recommendations
Institutional Ownership
APTO Latest News
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 18, 2024 (the “Meeting”). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Company entitled to be voted, were represented by shareholders present or represented by proxy at the Meeting.
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AML TUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical Study TUS+VEN+Azacitidine (AZA) Triplet Trial to Treat Newly Diagnosed AML Patients; Clinical Sites Being Activated SAN DIEGO and TORONTO, June 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced a clinical poster presentation and a preclinical e-poster at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain. Tuspetinib (TUS) is being developed as a TUS + venetoclax (VEN) + hypomethylating agent (HMA) triple drug combination (or TUS+VEN+HMA triplet) as frontline therapy for newly diagnosed AML patients.
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aptose Biosciences Inc. will be holding its Q1 2024 Earnings Conference Call on May 14, 2024 at 5:00 PM ET. Key company representatives participating in the call include Susan Pietropaolo, William Rice, Rafael Bejar, and Fletcher Payne. The conference call will be moderated by Joe Pantginis from H.C. Wainwright. Good afternoon, and welcome to the call.
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date: Tuesday, March 26, 2024 Time: 5:00 PM ET Audio Webcast Only: link Q&A Participant Registration Link*: link (https://register.vevent.com/register/BIe69f08fc83634a6aa38bf7081d82c6a2) *Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique PIN, which are required to access the conference call.
Aptose Biosciences (NASDAQ: APTO ) stock is on the move Friday after announcing details for a public offering of the clinical-stage biotechnology company's shares. Aptose Biosciences is selling 4,912,280 shares of its common stock at a price of $1.71 per share.
Aptose Biosciences Inc. (NASDAQ:APTO ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Operator Good afternoon. My name is Hope, and I will be your conference operator today.
SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date: Thursday, November 9, 2023 Time: 5:00 PM ET Audio Webcast Only: link Q&A Participant Registration Link*: link (https://register.vevent.com/register/BIb770b610b0744016870ec2150989ea78) *Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique PIN, which are required to access the conference call.
What type of business is Aptose Biosciences?
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
What sector is Aptose Biosciences in?
Aptose Biosciences is in the Healthcare sector
What industry is Aptose Biosciences in?
Aptose Biosciences is in the Biotechnology industry
What country is Aptose Biosciences from?
Aptose Biosciences is headquartered in Canada
When did Aptose Biosciences go public?
Aptose Biosciences initial public offering (IPO) was on 16 March 1992
What is Aptose Biosciences website?
https://www.aptose.com
Is Aptose Biosciences in the S&P 500?
No, Aptose Biosciences is not included in the S&P 500 index
Is Aptose Biosciences in the NASDAQ 100?
No, Aptose Biosciences is not included in the NASDAQ 100 index
Is Aptose Biosciences in the Dow Jones?
No, Aptose Biosciences is not included in the Dow Jones index
When does Aptose Biosciences report earnings?
The next expected earnings date for Aptose Biosciences is 09 August 2024